Meta-Analysishigh evidence
Comparative Efficacy of Promising Targets in the Treatment of Metabolic Dysfunction-associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Network Meta-analysis.
Journal of clinical and translational hepatology·August 28, 2026·PMID 42724131
Why it mattersMASLD is a leading cause of liver disease with limited approved therapies. This analysis provides comparative efficacy rankings across emerging drug classes, helping clinicians understand which mechanisms may best address fibrosis, steatohepatitis, and metabolic comorbidities.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled